SAMMARTANO, VINCENZO
 Distribuzione geografica
Continente #
EU - Europa 1.699
NA - Nord America 1.191
AS - Asia 873
SA - Sud America 181
AF - Africa 15
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.962
Nazione #
US - Stati Uniti d'America 1.154
RU - Federazione Russa 584
SG - Singapore 355
IT - Italia 306
CN - Cina 244
IE - Irlanda 215
DE - Germania 177
BR - Brasile 148
GB - Regno Unito 116
FI - Finlandia 109
HK - Hong Kong 75
SE - Svezia 59
KR - Corea 56
FR - Francia 51
IN - India 39
VN - Vietnam 37
CA - Canada 23
NL - Olanda 15
AR - Argentina 13
PL - Polonia 13
JP - Giappone 12
MX - Messico 12
ES - Italia 10
AT - Austria 9
BD - Bangladesh 9
CZ - Repubblica Ceca 9
ZA - Sudafrica 8
IR - Iran 6
UA - Ucraina 6
CO - Colombia 5
EC - Ecuador 5
IQ - Iraq 5
LT - Lituania 5
SA - Arabia Saudita 4
BO - Bolivia 3
ID - Indonesia 3
MY - Malesia 3
PK - Pakistan 3
TR - Turchia 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
CH - Svizzera 2
CI - Costa d'Avorio 2
CL - Cile 2
HR - Croazia 2
IL - Israele 2
JO - Giordania 2
LA - Repubblica Popolare Democratica del Laos 2
MA - Marocco 2
PY - Paraguay 2
UZ - Uzbekistan 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
BE - Belgio 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GR - Grecia 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NP - Nepal 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TL - Timor Orientale 1
TN - Tunisia 1
UG - Uganda 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.962
Città #
Dallas 275
Singapore 260
Dublin 214
Moscow 151
Munich 135
Ashburn 118
Santa Clara 96
Hefei 79
Southend 76
Hong Kong 74
Siena 73
Helsinki 72
Beijing 65
Chandler 58
Seoul 54
Fairfield 45
New York 44
Los Angeles 38
Florence 30
Woodbridge 24
Turku 23
Cambridge 20
Rome 20
Milan 19
Seattle 19
São Paulo 19
Houston 17
Princeton 17
Ho Chi Minh City 15
Bengaluru 14
Nuremberg 14
Shanghai 14
Wilmington 14
Buffalo 12
Lappeenranta 12
Turin 12
Warsaw 12
Portsmouth 11
Redondo Beach 11
Lauterbourg 10
San Francisco 10
Chicago 9
Denver 9
London 9
Messina 9
Washington 9
Brooklyn 8
Rio de Janeiro 8
The Dalles 8
Tokyo 8
Atlanta 7
Boston 7
Johannesburg 7
Brno 6
Frankfurt am Main 6
Mumbai 6
Orem 6
Toronto 6
Chennai 5
Dearborn 5
Fremont 5
Hanoi 5
Montreal 5
Querétaro 5
Vienna 5
Dong Ket 4
Mexico City 4
Modena 4
Naples 4
Phoenix 4
Porto Alegre 4
San Mateo 4
Secaucus 4
Stockholm 4
Vancouver 4
Biên Hòa 3
Boardman 3
Brasília 3
Buscate 3
Columbus 3
Como 3
Dhaka 3
Düsseldorf 3
Grosseto 3
Haiphong 3
Hyderabad 3
Jacksonville 3
Morrinhos 3
Olomouc 3
Parma 3
Perugia 3
Ribeirão Preto 3
Sacramento 3
Seto 3
Tehran 3
Verona 3
Xi'an 3
Abidjan 2
Ambivere 2
Americana 2
Totale 2.571
Nome #
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 272
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 223
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 221
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin 207
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma 204
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia 192
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 189
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 181
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency 165
Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy 153
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients 152
Prospective monitoring of Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation: the fate of Peripheral Blood CD26+ Leukemia Stem Cells 151
Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant) 148
Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network) 147
Safety of COVID-19 mRNA vaccination in patients with history of acquired hemophilia A: a case series 145
Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS) 134
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 131
Functional imaging in the evaluation of treatment response in multiple myeloma: the role of PET-CT and MRI 124
Prognostic value of CD47 overexpression measured by flow cytometry in patients with acute myeloid leukemia 124
Anti-BCMA novel therapies for multiple myeloma 120
The slower antibody response in myelofibrosis patients after two doses of MRNA sars-COV-2 vaccine calls for a third dose 116
Central nervous system myeloma and unusual extramedullary localizations: real life practical guidance 113
Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia 109
Finding the balance between immunoparesis recovery and multiple myeloma responses after autologous stem cell transplantation in the era of maintenance therapy and novel drugs 94
Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy 90
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies 81
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies 77
Totale 4.063
Categoria #
all - tutte 13.683
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.683


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021121 0 0 0 0 0 15 20 21 11 34 11 9
2021/2022146 11 8 10 19 1 5 2 3 5 13 33 36
2022/2023330 13 32 35 33 23 37 24 32 23 6 66 6
2023/2024491 9 14 48 32 30 114 157 16 13 27 4 27
2024/20251.118 34 31 99 54 86 106 96 87 119 50 134 222
2025/20261.744 170 301 265 392 595 21 0 0 0 0 0 0
Totale 4.063